New Warnings For Medtronic, Inc.'s Paradigm Insulin Pumps

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Australian regulators again warn users of Medtronic's Paradigm insulin pumps of the danger of accidental insulin overdose. Australian healthcare regulators issued renewed warnings to patients using Medtronic's (NYSE:MDT) Paradigm insulin pumps, cautioning that an accidental button-press may result in a potentially dangerous overdose. The Paradigm pumps, which deliver both continuous and bolus-based doses of insulin, can switch from a zero bolus setting to a maximum dose with a single click when in certain modes.

Help employers find you! Check out all the jobs and post your resume.

Back to news